Abdominal Wall Endometriosis After Cesarean Section: A Systematic Review of Clinical Presentation, Timing, and
Noemi Salmeri1, Alessia Ragusi2, Camilla Buffo3
1Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Università degli Studi di Milano (Drs. Salmeri, Somigliana, and Vercellini), Milano, Italy; Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Drs. Salmeri, Ragusi, Viganò, Somigliana, and Vercellini), Milano, Italy.
Objective:
To synthesize the available evidence on abdominal wall endometriosis (AWE) after cesarean section (CS) by characterizing its clinical features and timing of presentation, and to determine how often prior or concomitant endometriosis is present, in order to explore whether AWE can develop independently of individual predisposition.
Data Sources:
Systematic search up to September 22, 2025.
Methods Of Study Selection:
Eligibility was defined using the following framework: Population: women with histologically confirmed AWE following CS; Intervention: diagnostic evaluation and surgical excision with histological confirmation; Comparator: no comparator group was required, though exploratory comparisons were performed between women with and without other forms of endometriosis; Outcomes: clinical, diagnostic, and surgical timelines; Study type: case reports or series. The review followed PRISMA 2020 guidelines.
Tabulation, Integration, And Results:
A total of 158 studies met inclusion criteria, accounting for 484 cases across all world regions. Median age at diagnosis was 33 years (interquartile ranges [IQR] 29-36). Median time from CS to symptoms was 26 months (IQR 12-48), and from CS to diagnosis 48 months (IQR 36-72). Abdominal pain (96%, 95% confidence interval [CI] 93.7-97.6) and a palpable mass (94.1%, 95% CI 91.6-96.1) were the most frequent symptoms. Subfascial involvement was most common (52.8%, 95% CI 45.2-60.4). Recurrence occurred in 5.3% (95% CI 2.8-8.8). Prior endometriosis was reported in 9.4% (95% CI 5.1-15.5), and concomitant disease in 8.1% (95% CI 3.7-14.8). Exploratory comparisons of clinical timelines revealed no significant differences between women with and without other forms of endometriosis.
Conclusion:
AWE after CS is uncommon but expected to rise as CS rates increase. The rarity of coexisting endometriosis supports iatrogenic implantation per se as a sufficient initiating event. Its extrapelvic location and the well-defined timing of tissue dissemination make AWE an especially informative in vivo model for studying early mechanisms of endometriosis pathogenesis.
